21.23k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
|Watchlist||Change today||1-month return||1-year return||Total return|
|The Fight Against COVID19||-1.91%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||161.98||-3.24||-1.96%||4:00 pm GMT-4||12.99M||7.16M||426.56B|
|PFE||Pfizer Inc.||38.81||-0.67||-1.70%||4:02 pm GMT-4||33.21M||26.94M||217.25B|
|ABBV||AbbVie Inc.||113.12||-1.78||-1.55%||4:03 pm GMT-4||6.95M||6.62M||199.79B|
|SNY||Sanofi||52.86||-0.38||-0.71%||4:00 pm GMT-4||5.68M||1.32M||133.96B|
|GSK||GlaxoSmithKline plc||39.84||-0.73||-1.80%||4:00 pm GMT-4||9.92M||4.64M||100.23B|
|GILD||Gilead Sciences, Inc.||66.61||-0.61||-0.91%||4:00 pm GMT-4||10.09M||7.18M||83.54B|
|MRNA||Moderna, Inc.||199.19||-3.28||-1.62%||4:00 pm GMT-4||6.66M||9.32M||79.98B|
|REGN||Regeneron Pharmaceuticals, Inc.||537.92||+1.91||+0.36%||4:00 pm GMT-4||914.79k||815.33k||57.31B|
|TAK||Takeda Pharmaceutical Company Limited||16.55||-0.36||-2.13%||4:00 pm GMT-4||4.43M||2.42M||52.79B|
|BNTX||BioNTech SE||212.42||-1.78||-0.83%||4:00 pm GMT-4||2.26M||3.04M||51.30B|
|NVAX||Novavax, Inc.||174.41||-5.48||-3.05%||4:00 pm GMT-4||2.88M||3.75M||12.92B|
|VIR||Vir Biotechnology, Inc.||46.15||+2.33||+5.32%||4:00 pm GMT-4||1.77M||689.34k||6.00B|
|INO||Inovio Pharmaceuticals, Inc.||8.49||-0.33||-3.74%||4:00 pm GMT-4||5.60M||8.39M||1.78B|
The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.
Switzerland plans to allow 12- to 15-year olds to receive vaccinations against COVID-19 as soon as next week, government vaccine chief Christoph Berger told Swiss newspaper NZZ in an interview published on Sunday. "Young people who want to be vaccinated should be given the opportunity," Berger told NZZ, adding the government's approval was expected to be communicated next week. "For those with pre-existing conditions or those in contact with immunocompromised individuals who are at risk, vaccination makes sense," he said, adding that - unlike for older populations - it would not be necessary to target a vaccination rate for the 12- to 15-year old population.
COVID-19 vaccines delivered by Israel and then rejected by the Palestinian Authority (PA) over their expiration date were fine, the Israeli health ministry said on Saturday. Israel and the PA on Friday announced a vaccine swap deal that would have seen Israel send up to 1.4 million doses of the vaccine made jointly by Pfizer (PFE.N) and BioNTech (22UAy.DE) to the PA in exchange for receiving a reciprocal number of doses later this year. But soon after the announcement, the PA cancelled the deal and said it had sent an initial shipment of around 90,000 doses back to Israel.